RxDoctor Payments Data

Tara Nimtz

Nurse Practitioner · la Porte, INNPI 1104437631

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 60 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$420
  • Biohaven Pharmaceuticals, Inc.$119
  • Novo Nordisk$86
  • Takeda Pharmaceuticals U.S.A., Inc.$69
  • Tris Pharma Inc$57
  • Biohaven Pharmaceutical Holding Company Ltd.$48
  • plus $270 from 10 others

What the payments were for

  • Food & beverage$1,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,069 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$805
Medicare patients
23
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$82,295
OzempicSemaglutide48$64,003
TrulicityDulaglutide26$34,097
JanuviaSitagliptin Phosphate18$21,160
FarxigaDapagliflozin Propanediol23$12,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,588
EliquisApixaban14$8,425
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,245
Breo ElliptaFluticasone/Vilanterol14$5,239
Humalog Kwikpen U-100Insulin Lispro19$5,229
Albuterol Sulfate HfaAlbuterol Sulfate129$3,613
Novolog FlexpenInsulin Aspart13$2,949
Atorvastatin Calcium208$1,367
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$981
Levothyroxine Sodium81$804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$86$64,00348 claims
Lilly USA, LLCTrulicity$24$34,09726 claims
GSKTrelegy Ellipta, Breo Ellipta$28$14,82628 claims
PfizerEliquis$47$8,42514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in la Porte

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →